For the Inventor, By the Inventor

Enter assignee name

Durham, NC, United States of America

Trimeris, Inc.

USPTO Granted Patents = 31

% Expired Patents = 16.1

CIPO Patents = 4

EPO Patents = 1

Forward Citations = 465

Loading Chart...

Loading Chart...

37 inventors (with patents filed for the assignee):

Dennis Michael Lambert (21 out of 24 patents)

Shawn O'Lin Barney (13 out of 14 patents)

Stephen Robert Petteway (13 out of 16 patents)

4. Brian L Bray (7 out of 13 patents)

5. Gene Merutka (7 out of 7 patents)

6. Kelly Guthrie (5 out of 13 patents)

7. Shawn Barney (5 out of 6 patents)

8. Mohmed K Anwer (5 out of 5 patents)

9. Myung-Chol Kang (4 out of 5 patents)

10. Huyi Zhang (3 out of 10 patents)

11. Nicolai A Tvermoes (3 out of 3 patents)

12. John William Lackey (3 out of 3 patents)

13. Paul Erickson Friedrich (3 out of 4 patents)

14. John Dwyer (2 out of 2 patents)

15. Stephen E Schneider (2 out of 11 patents)

Core Competencies:

HIV Fusion Inhibitors

Antiviral Compounds

Peptide Synthesis

Pharmaceutical Composition

Viral Fusion

Respiratory Syncytial Virus

Combinatorial Therapy

Hybrid Polypeptides

Biological Properties

Peptide-Polymer Conjugates

Epstein-Barr Virus

Measles Virus

31 patents: Sort by Forward Citations

1. 8034899 - HIV fusion inhibitor peptides with improved biological properties (2011-10-11),

2. 7794725 - Isolated peptides derived from human immunodeficiency virus types 1 and 2 containing fusion inhibitory domains (2010-09-14),

3. 7556813 - Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides (2009-07-07),

4. 7514397 - Methods for inhibition of membrane-fusion-associated events, including Hepatitis B virus transmission (2009-04-07),

5. 7456251 - HIV fusion inhibitor peptides with improved biological properties (2008-11-25),

6. 7297784 - DNA encoding T-1249 and other viral fusion inhibitor peptides useful for treating aids (2007-11-20),

7. 7045552 - Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy (2006-05-16),

8. 7030150 - Benzimidazole compounds and antiviral uses thereof (2006-04-18),

9. 6951717 - Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission (2005-10-04),

10. 6861059 - Methods and compositions for treatment of HIV-1 infection using antiviral compounds in simultaneous or sequential combinations (2005-03-01),

11. 6750008 - Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission (2004-06-15),

12. 6656906 - Hybrid polypeptides with enhanced pharmacokinetic properties (2003-12-02),

13. 6623741 - Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission (2003-09-23),

14. 6562787 - Hybrid polypeptides with enhanced pharmacokinetic properties (2003-05-13),

15. 6541020 - Methods and compositions for administration of therapeutic reagents (2003-04-01),

Trimeris, Inc. is a biotechnology company based in Durham, North Carolina, specializing in the development of innovative therapeutics for the treatment of viral infections. The company focuses on advancing its proprietary technologies to create effective solutions for unmet medical needs, particularly in the field of HIV treatment. With a commitment to research and development, Trimeris aims to enhance patient outcomes through its cutting-edge approaches in antiviral drug discovery and development.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

31 Patents

#34 in Durham, NC

#255 in North Carolina

#10,912 in US

#21,217 in the World

Durham, NC, United States of America

Trimeris, Inc.

Forward Citations = 465

37 inventors:

Dennis Michael Lambert (21 out of 24 patents)

Shawn O'Lin Barney (13 out of 14 patents)

Stephen Robert Petteway (13 out of 16 patents)

4. Brian L Bray (7 out of 13 patents)

5. Gene Merutka (7 out of 7 patents)

Please report any incorrect information to [email protected]

Loading…